November 2018 Shareholder Newsletter

Kazia Therapeutics is pleased to make its November 2018 newsletter available.


Morgans interview with Kazia CEO Dr James Garner

Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.


Potential glioblastoma therapy GDC-0084 presented to Finance News Network audience

Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week.


Kazia enters clinical collaboration to study use of brain cancer drug GDC-0084 in breast cancer

The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.


Australian clinical trial of ovarian cancer therapy Cantrixil pivotal for cancer stem cell research

The Australian phase 1 clinical trial of the drug Cantrixil for recurrent ovarian cancer could shape the next wave of clinical research into drugs targeting cancer stem cells, a peer-reviewed paper published in Expert Opinion on Orphan Drugs this month has found.


Sydney Shareholder Information Session July 2018

Kazia Therapeutics hosted briefing sessions for shareholders in Sydney and Melbourne this month.


What makes our cancer therapies different

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase.


Cantrixil phase 1 clinical study: Dr James Garner discusses the interim data

Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.


KAZIA Shareholder Information Sessions June 2018

Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.


Kazia Therapeutics investor newsletter - May 2018

Kazia Therapeutics is pleased to make its May 2018 newsletter available to investors via this link.


Trials start on new treatment for ovarian cancer, the silent killer in Australia

A breakthrough new treatment for ovarian cancer that aims to stop the disease returning by killing off the cancer’s stem cells is undergoing safety trials in Australia.


Emerging oncology researcher says women lose out as ovarian cancer treatments lag

A prominent Australian oncology researcher says ovarian cancer patients are losing out as badly-needed funds and clinical attention is focused on more prominent – yet not as deadly – women’s diseases.


Meet our Scientific Advisory Board

Kazia was delighted recently to have the members of our Scientific Advisory Board gather in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer. Stuart Roberts, Senior Analyst at NDF Research took the opportunity to conduct wide-ranging interviews with each of the SAB members, which provide rich insights into their work. 


Why GDC-0084 for glioblastoma: Q&A with Kazia CEO Dr James Garner

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).


GDC-0084 and glioblastoma multiforme

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing a new therapy called GDC-0084 to treat the rare and deadly brain cancer, glioblastoma multiforme (GBM).


Novogen changes name to Kazia Therapeutics

CommSec's Tom Piotrowski talks with Kazia Executive Director and CEO Dr James Garner about our company name change to Kazia Therapeutics.


Novogen becomes Kazia Therapeutics

Australian biotechnology company, Novogen has announced that it will change its name to Kazia Therapeutics and that it will consolidate its share register, after the overwhelming majority of shareholders voted in favour of the proposed changes at the company's AGM held in Sydney last week.